Cognizant has officially entered into a strategic agreement with Alnylam Pharmaceuticals, a prominent biopharmaceutical firm renowned for its groundbreaking work in RNA interference (RNAi) therapeutics. Under this partnership, Cognizant will function as a critical IT Managed Services provider for Alnylam, with a primary focus on expanding its IT infrastructure and enhancing its ability to bring transformative medicines to market swiftly and efficiently.
Cognizant has been chosen as the trusted technology partner tasked with overseeing Alnylam’s global infrastructure and operations, encompassing areas such as cloud solutions, security protocols, platform management, application development, and sophisticated data analytics. By utilizing Cognizant’s robust managed services frameworks and innovative tools, this collaboration looks to significantly boost automation, decrease operational workloads, and provide greater transparency in business decision-making, all while promoting cohesive performance accountability across the board.
“By leveraging Cognizant’s deep expertise in the life sciences sector along with their advanced managed services frameworks, we aim to significantly accelerate our business outcomes and ultimately enhance customer experiences,” stated Larry Egan, Vice President of Strategic Technologies at Alnylam, highlighting the collaborative potential of the partnership.
Currently, thirty of the top global pharmaceutical companies collaborate with Cognizant to deploy and manage cutting-edge technology solutions. These collaborations enable them to expedite the market introduction of innovative drugs, efficiently manage global supply chains and manufacturing systems, and navigate the complexities of regulatory compliance.
“We are excited to partner with Alnylam on its pivotal IT transformation journey,” remarked Mohammad Haque, SVP, Global Large Deals Lead and BU Head of Life Sciences at Cognizant. “By leveraging our vast experience with major pharmaceutical companies and our significant investments in AI, we are committed to accelerating Alnylam’s ambitious business goals. As a strategic ally, we eagerly look forward to facilitating Alnylam’s growth and supporting their mission to deliver groundbreaking medicines that address both rare and widespread diseases.”
Larry Egan, Vice President of Strategic Technologies at Alnylam
“By leveraging Cognizant’s expertise in the life sciences sector and innovative managed services frameworks, we will aim to accelerate our business outcomes and ultimately improve customer experiences.”
Mohammad Haque, SVP, Global Large Deals Lead and BU Head, Life Sciences at Cognizant
“We are thrilled to partner with Alnylam on its IT transformation journey. We will bring our extensive experience with large pharmaceutical companies, along with investments in AI, to accelerate Alnylam’s business goals. As a strategic partner, we look forward to helping Alnylam grow its business and continue delivering transformative medicines to treat both rare and prevalent diseases.”
**Interview with Larry Egan, Vice President of Strategic Technologies at Alnylam Pharmaceuticals**
**Interviewer:** Thank you for joining us, Larry. Cognizant and Alnylam have recently entered into a strategic agreement. Can you tell us more about what prompted this collaboration?
**Larry Egan:** Absolutely! We chose to partner with Cognizant because of their deep expertise in the life sciences sector and their advanced managed services frameworks. Our goal is to enhance our IT infrastructure, which is crucial in bringing our transformative RNAi therapeutics to market more effectively. In an industry where time literally equates to lives saved, collaboration with a trusted technology partner is essential.
**Interviewer:** What specific areas will Cognizant be focusing on within Alnylam’s operations?
**Larry Egan:** Cognizant will oversee our global infrastructure and operations. This includes a variety of critical areas such as cloud solutions, security protocols, platform management, application development, and data analytics. Their focus will ultimately help us streamline our operations, drive automation, and decrease manual workloads, allowing our teams to concentrate more on research and development.
**Interviewer:** That sounds promising! How do you foresee this partnership improving decision-making and accountability within your organization?
**Larry Egan:** By leveraging Cognizant’s robust managed services and innovative tools, we’re looking to enhance transparency in our operations. Improved data analytics will provide clearer insights, which will lead to more informed business decisions. Additionally, the structured performance accountability that Cognizant promotes will ensure everyone is aligned on our objectives, facilitating better outcomes across all teams.
**Interviewer:** It’s great to hear about the mutual benefits of this partnership. Looking ahead, what are your expectations or goals for the collaboration with Cognizant?
**Larry Egan:** Our primary expectation is to accelerate our business outcomes significantly. By enhancing our IT capabilities and operational efficiency, we aim not only to improve our time-to-market for new therapies but also to enhance overall customer experiences. We believe that a strong IT foundation will empower us to navigate the complexities of the biopharmaceutical landscape more effectively.
**Interviewer:** Thank you, Larry, for sharing your insights. It truly sounds like a strategic move that will benefit both Alnylam and its mission in the biopharmaceutical field.
**Larry Egan:** Thank you for having me! We’re excited about the potential this partnership holds and the positive impact it can have on patients’ lives.